PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Stanley C. Jordan, MD, FASN, FAST - Visualizing Progress in the Treatment of Chronic Active Antibody-Mediated Rejection: A Closer Look at the Clinical Potential of Targeting IL-6 to Improve Outcomes in the Kidney Transplant Setting
Go online to PeerView.com/RBD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated video activity, Dr. Stanley C. Jordan discusses the rationale for targeting IL-6 in chronic active antibody-mediated rejection, as well as the use of anti–IL-6 agents for the treatment of chronic active antibody-mediated rejection in the kidney transplant setting. Upon completion of this activity, participants should be better able to: Utilize the Banff classification to characterize the nature and extent of kidney transplant rejection in order to guide treatment; Discuss the rationale for targeting IL-6 as a therapeutic approach to chronic active antibody-mediated rejection in kidney transplant recipients; and Evaluate the efficacy, safety, and clinical potential of anti–IL-6 agents currently in development for the treatment of chronic active antibody-mediated rejection in the kidney transplant setting